Overview
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
Status:
Completed
Completed
Trial end date:
2006-02-01
2006-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Criteria
Inclusion Criteria:- Adults with active rheumatoid arthritis for greater than 6 months and evidence of
inflammation.
Exclusion Criteria:
- Subjects who have conditions precluding the use of cytokine inhibitors or subjects who
require DMARDs other than hydroxychloroquine or sulfasalazine are excluded.